Getting Your Products Reimbursed by Private Payers

Jeffrey Bush Director, Corporate Reimbursement Becton, Dickinson and Company (BD)



What Outcomes Do Payers Expect?

- Payers Require Medical Evidence that a Given New <u>Technology Brings Value to Members & Ideally to</u> <u>the Bottom Line</u>
 - Stronger Evidence = More Enthusiastic Payer
 - Greater Savings = More Enthusiastic Payer
 - Sooner Savings Can Be Realized = Enthusiastic Payer
 - Randomized Control Trial (RCT) Demonstrating Value/Savings is Consensus Gold Standard
 - Most Medical Device Trials Are Not RCT's
 - FDA Challenges with RCT's for Medical Devices



Be Prepared to Defend Your Choice of Evidence Collection

RCT

RCT, Insignificant

Non-Random Historical Cohort Comparison Non-Random Concurrent Cohort Comparison

Case Series W/O Ctrl Subjects

From criteria proposed by Cook et al, Rules of evidence Chest 1992; 305S-311S



Medical Devices & Evidence

- Examples of Devices that have provided high level of evidence
 - Standard Stents
 - Drug Eluting Stents
 - ICD's
 - Biventricular Pacemakers (MIRACLE trial)




Device Outcomes Examples

- RCT's & Modeled Outcomes
 - Examples of Device Based Outcomes Studies
 - MIRACLE Trial for CRT
 - RAVEL, SIRIUS, C-SIRIUS & E-SIRIUS for DES
 - D.K. Owens et al, Cost-Effectiveness of Implantable Cardioverter Defibrillators, NEJM, Oct 6, 2005.
 - Stents Numerous



Understand Payer Evidence Expectations



From Bryan Luce & Ann Elixhauser, "Documenting the Value of a Medical Device," Medical Device & Diagnostic Insustry, January, 1999.

Consider Outcomes Alternatives

 Outcomes Modeling –PC Based Modeling of Cost-Benefit E.g., Markov Simulations -Comparative Effectiveness CPLYS/CPQALYS Savings Estimates -Require Variable Input Must Collect Some Data (Clin Trial or Other)



Drug Eluting Stent Example

(JAMC • 1er FÉVR. 2005; 172 (3))




Fig. 1: Markov model, showing cost and clinical outcomes after percutaneous coronary intervention (PCI) with stenting in 6-month intervals. After initial PCI, patients are at risk of clinical restenosis over the first year. During this year, they may progress through 5 discrete health states: 1) alive with no clinical restenosis (i.e., event-free), 2) clinical restenosis as determined by the need for a subsequent coronary artery bypass graft (CABG), 3) clinical restenosis as determined by the need for repeat PCI, 4) repeat catheterization with no subsequent revascularization procedure (defined as no PCI or CABG in the ensuing 3 months) and 5) death. Restenosis is considered to occur only in the first year after initial PCI.¹ Thereafter, patients have an ongoing long-term risk of death. CATH = catheterization.

QALY Assessment of Stenting

TABLE 5. Cost-Effectiveness of Stenting and Abciximab in the CADILLAC Trial Under Alternate Assumptions Regarding 1-Year Mortality

Scenario	∆ Cost (95% Cl),* US \$	∆ QALYs (95% Cl)*	C/E Ratio (\$/QALY)	% <\$50 000 per QALY*	% Dominant*	% Dominated*
Stent vs PTCA						
Primary analysis	169 (-821 to 1177)	0.015 (0.011 to 0.019)	11237	86.4	38.2	0.0
With mortality differences	242 (-961 to 1368)	0.034 (-0.164 to 0.247)	7067	60.2	22.5	24.7
Abciximab vs no abciximab						
Primary analysis	1244 (289 to 2288)	-0.002 (-0.006 to 0.002)	Dominated	0.1	0.1	75.8
With mortality differences	1468 (205 to 2385)	0.058 (-0.130 to 0.266)	25 136	64.0	1.0	26.5

*Percentages and CIs are based on 1000 bootstrap simulations of trial results.




Communicate With Tech Assessors

- Blue Cross & Blue Shield TEC TA for Association Members & Others
- Hayes TA for Customers
- ECRI TA for Customers
- Aetna Internal TA Group
- United HealthCare Internal TA's
- Kaiser Some Internal TA's



Design Trials With Outcomes Data Collection in Mind



DON'T!!!!!

 Expect Payers to Embrace Your Product If You Can't Prove What's In It for Them



Next Steps

Worked with Payers/Tech Assessors
Collected Your Evidence
Developed Economic Modeling
Prepared Your Best Case
NOW WHAT?





Next Steps

- Have a Plan to Reach All Relevant Stakeholders
- Medicare Precedent is Often Important, if Established
- Peer Payer Implementation Creates Competitive Disadvantage
- Reliance on Good Evidence Alone Naïve
- Influence Payers from Multiple Angles
 - Develop Provider and Patient Champions



Case Example

- Liquid based cytology and Aetna
 - Despite strong study data, Aetna refused coverage
 - Advocacy campaign leveraged upon senior medical directors and executives
 - Provider & Patient Focused
 - Overriding internal opposition, Aetna reversed coverage decision



THANK YOU!!!!



Stent RCT's

Table 1: Results of RCTs of PTCA vs Stents

MANNA

Trial N of patients	Immediate clinical results:	Immediate angiographic	Longer term clinical results:	Longer term angiographic	Comments
it of patients	stent v PTCA	results: stent v PTCA	stent v PTCA	results for stent v PTCA	
BENESTENT⁴⁻⁸ 516	Increased bleeding, vascular complications, LOS	Increased MLD. Decreased % stenosis	Increased event free survival at 12 mths. Decreased risk of PTCA and of any event 7 and 12 mths.	Increased reference diameter. Decreased restenosis rate and % stenosis at 7 mths.	Clearly reported. Includes subgroup follow up of exercise testing showing no difference between stent and PTCA groups.
STRESS ⁹⁻¹⁴ 316	No significant differences	Increased MLD. Decreased % stenosis	No significant differences	Increased MLD. Decreased restenosis rate and %stenosis at 7 mths	Target vessel revascularization result p=0.06 taken to be statistically significant by trial authors but not in this review.
Switzerland ¹⁵ 84	Increased vascular complications, LOS	Increased MLD. Decreased % stenosis	No significant differences	No significant difference restenosis rate, % stenosis, MLD	Different stent which is more radio-opaque so borderline restenosis more difficult to judge
<i>Italy</i> ¹⁶ 120	Increased vascular complications, LOS	Increased MLD. Decreased % stenosis	Increased event free survival	Increased MLD. Decreased restenosis rate , % stenosis.	Some clinical results have to be inferred from text as presentation of results not clear
BENESTENT II ¹⁷ 823	No significant differences	Increased MLD. Decreased % stenosis	Increased event free survival Decreased repeat PTCA	Increased MLD. Decreased % stenosis	Cost effectiveness data – stents more effective and more costly. Subgroup follow up of angiographic and clinical or clinical only - clinical follow up only have increased rate rpt PTCA.
SICCO ¹⁸	Increased	Increased MLD.	Increased angina free	Increased MLD.	Some clinical results have to



More Stent RCT's

117	bleeding at puncture site, LOS	Decreased % stenosis	survival	Decreased restenosis rate , % stenosis.	be inferred from text as presentation unclear.
GISSOC ¹⁹ 110	See longer term results	Increased MLD Decreased % stenosis	Increased LOS. Decreased TVA, recurrent ischaemia	Increased MLD. Decreased restenosis rate, reocclusion rate, % stenosis.	Does not state how occlusions were found at >30 days duration.
Britain²⁰ 60	No significant differences	Increased MLD. Decreased % stenosis	No significant differences	Increased MLD. Decreased reocclusion rate.	Some clinical results have to be inferred from text as presentation unclear.
GRAMI ²¹ 104	Increased TIMI flow, event free survival. Decreased recurrent ischaemia	Decreased % stenosis	Increased event free survival	Not given	Angiographic restenosis rates at follow up not reported
FRESCO ²² 150	Decreased recurrent ischaemia, repeat PTCA	Increased MLD Decreased restenosis	Decreased repeat PTCA, recurrent ischaemia	Increased MLD. Decreased restenosis rate.	Also includes results for non- randomised comparison group who had non-optimal PTCA result.
Holland ²³ 227	No significant differences	Increased MLD. Decreased % stenosis	Increased event free survival. Decreased re- current MI, repeat PTCA.	Not given	Anticoagulation therapy changed during trial from Warfarin to Ticlopidine

AND AND AND

